Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Insider Buys $99,600.00 in Stock

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) insider David Young bought 124,500 shares of the business’s stock in a transaction on Monday, January 27th. The shares were acquired at an average cost of $0.80 per share, for a total transaction of $99,600.00. Following the transaction, the insider now directly owns 205,405 shares in the company, valued at approximately $164,324. This trade represents a 153.88 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Processa Pharmaceuticals Stock Up 10.6 %

Shares of Processa Pharmaceuticals stock opened at $0.65 on Friday. The firm’s 50 day moving average price is $0.92 and its 200-day moving average price is $1.23. Processa Pharmaceuticals, Inc. has a 52-week low of $0.47 and a 52-week high of $3.31. The company has a market cap of $2.14 million, a P/E ratio of -0.19 and a beta of 0.62.

Processa Pharmaceuticals (NASDAQ:PCSA) last issued its quarterly earnings data on Wednesday, October 30th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.03). As a group, equities research analysts forecast that Processa Pharmaceuticals, Inc. will post -4.05 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Processa Pharmaceuticals in a research report on Thursday, December 5th.

Processa Pharmaceuticals Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.